Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Nov 8;9(3):705-713.
doi: 10.1159/000452403. eCollection 2016 Sep-Dec.

Ipilimumab-Induced Enteritis without Colitis: A New Challenge

Affiliations
Case Reports

Ipilimumab-Induced Enteritis without Colitis: A New Challenge

Marcus Messmer et al. Case Rep Oncol. .

Abstract

Introduction: Ipilimumab is an immune checkpoint inhibitor targeting cytotoxic T-lymphocyte associated antigen 4 (CTLA4), approved to treat metastatic melanoma. It was the first therapy shown to prolong survival in a large, randomized clinical trial. However, immune-related adverse events are common and can be severe. Enterocolitis is a common adverse event with ipilimumab, but enteritis without colitis has not been previously described.

Case report: An 83-year-old man presented to our hospital with grade 3 diarrhea for 5 days. One month prior, he had started treatment with ipilimumab for metastatic melanoma. On presentation, he was found to have severe electrolyte disturbances, including hyponatremia, hypokalemia, and acute kidney injury. Causes of infectious diarrhea were excluded, and he was treated with corticosteroids for presumed ipilimumab-associated enterocolitis. However, colonoscopy revealed normal mucosa, both grossly and on pathology of random biopsies. Steroids were weaned but his symptoms recurred. He then underwent upper endoscopy with enteroscopy. Biopsy of the duodenum was notable for acute inflammation, villous blunting, and other changes consistent with ipilimumab-associated injury. He was restarted on high-dose steroids and his symptoms resolved.

Discussion: Ipilimumab-induced enteritis is a serious and potentially life-threatening immune related adverse event that warrants prompt recognition and aggressive management. As in cases of ipilimumab-associated enterocolitis, steroids are an effective therapy. Enteritis without colitis should be suspected in patients on ipilimumab who present with severe diarrhea but have a normal colonoscopy.

Keywords: CTLA4 inhibitor; Colitis; Enteritis; Immunotherapy; Ipilimumab; Melanoma.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Colonoscopy was performed, which revealed grossly normal mucosa.
Fig. 2
Fig. 2
Random biopsies of the colon showed normal mucosa.
Fig. 3
Fig. 3
On enteroscopy, the small bowel appeared grossly unremarkable.
Fig. 4
Fig. 4
Random biopsies of the duodenum were taken, which revealed villous blunting (a), as well as acute inflammation, expansion of the lamina propria, and increased apoptotic bodies (b).

References

    1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723. - PMC - PubMed
    1. Pages C, Gornet JM, Monsel G, et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res. 2013;23:227–230. - PubMed
    1. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–133. - PMC - PubMed
    1. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532. - PubMed
    1. Quirk SK, Shure AK, Agrawal DK, et al. Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. Transl Res. 2015;166:412–424. - PMC - PubMed

Publication types